 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. Nasdaq: INFI Infinity or the Company, a clinical-stage biotechnology company developing eganelisib IPI-549, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2021 financial results and provided a corporate update. Adelene Perkins, Chief Executive Officer and Chair, Infinity Pharmaceuticals, said, Today we report data indicating that eganelisib r 